AstraZeneca (AZN) has released an update.
AstraZeneca announces promising results from the SUPERNOVA Phase III trial, where its investigational long-acting antibody, sipavibart, significantly reduced COVID-19 incidence in immunocompromised patients. The trial met primary endpoints, showing efficacy against various SARS-CoV-2 variants in a population highly susceptible to COVID-19 complications. AstraZeneca is now engaging with global regulatory authorities to make sipavibart available to this vulnerable group.
For further insights into AZN stock, check out TipRanks’ Stock Analysis page.
